Evidence map›Paper›PMID 42446931›Full record

ArticleJCI insight2026

A large animal model of heritable pulmonary arterial hypertension using BMPR2 gene-edited sheep.

Sanjeev A Datar, Nicholas Werry, Austin R Brown, Devon S Fitzpatrick, Oluwafemi Falade, Josephine F Trott, Rachel Hutchings, Elena K Amin, Jessica M Morgan, Hythem Nawaytou and 9 more

Abstract read
In one paragraph

Article in JCI insight, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Sanjeev A DatarDepartment of Pediatrics, UCSF, San Francisco, California, USA.
Nicholas WerryDepartment of Animal Science, and.
Austin R BrownDepartment of Animal Science, and.
Devon S FitzpatrickDepartment of Animal Science, and.
Oluwafemi FaladeDepartment of Animal Science, and.
Josephine F TrottDepartment of Animal Science, and.
Rachel HutchingsDepartment of Pediatrics, UCSF, San Francisco, California, USA.
Elena K AminDepartment of Pediatrics, UCSF, San Francisco, California, USA.
Jessica M MorganSchool of Veterinary Medicine, UCD, Davis, California, USA.
Hythem NawaytouDepartment of Pediatrics, UCSF, San Francisco, California, USA.
Gail H DeutschDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
Eric G JohnsonSchool of Veterinary Medicine, UCD, Davis, California, USA.
Omar A Gonzales VieraSchool of Veterinary Medicine, UCD, Davis, California, USA.
Thomas F BishopDepartment of Animal Science, and.
Tara Urbano BeachSchool of Veterinary Medicine, UCD, Davis, California, USA.
Bret R McNabbSchool of Veterinary Medicine, UCD, Davis, California, USA.
Eric D AustinSchool of Medicine, Vanderbilt University, Nashville, Tennessee, USA.
Jeffery R FinemanDepartment of Pediatrics, UCSF, San Francisco, California, USA.
Alison L Van EenennaamDepartment of Animal Science, and.

Funding

PERINATAL PULMONARY HYPERTENSION: DEVELOPMENT MEDIATORSR01HL061284 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FINEMAN, JEFFREY R · 1999 to 2016
$8.3M
Altered Lymphatic Function and Development in Congenital Heart DiseaseR01HL133034 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Sanjeev A. Datar · 2016 to 2026
$6.4M
NHLBI NIH HHS R01 HL061284NHLBI NIH HHS R01 HL133034
6 · The paper itself

Abstract

Pulmonary arterial hypertension (PAH) is a rare vascular disorder characterized by elevated pressure in pulmonary arteries, eventually leading to right ventricular failure. Approximately 50% of pediatric disease and 20% of adult disease can be linked to a genetic mutation, with nearly 70% of these cases involving mutations in the bone morphogenetic protein receptor type 2 (BMPR2) locus. Investigations using rodent models have made substantial advances in our understanding of BMPR2 signaling; however, limited data exist regarding the onset and course of PAH, and etiologies for phenotypic expression in these patients remain unknown. In this work, we describe the development of an ovine model of heritable PAH. Because homozygous disruption of BMPR2 is embryonic lethal, we developed heterozygous BMPR2-edited (BMPR2+/-) sheep by using a PAM-disrupting synonymous single-stranded oligodeoxyribonucleotide alongside a single guide RNA and Cas9-mediated gene editing strategy. The resulting BMPR2+/- lambs demonstrated cardiac and pulmonary vascular pathology that are consistent with BMPR2 mutation-driven PAH observed in humans. Given the genetic and physiological similarities of BMPR2+/- sheep to humans with heritable PAH, this large animal model will serve as a vital platform for mechanistic molecular studies and will provide a much-needed preclinical model for extensive treatment evaluations.

Indexed as

Bone Morphogenetic Protein Receptors, Type IIFamilial Primary Pulmonary HypertensionGene EditingPulmonary Arterial HypertensionAnimalsDisease Models, AnimalFemaleHumansMutationPulmonary ArterySheepBone Morphogenetic Protein Receptors, Type IICardiologyCardiovascular diseaseMolecular geneticsPulmonologyVascular biology

Identifiers

PMID42446931
PMCPMC13502180

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.